Email updates

Keep up to date with the latest news and content from Genome Biology and BioMed Central.

Research news

Antibody fingerprint

Jonathan B Weitzman

Author Affiliations

Genome Biology 2003, 4:spotlight-20030102-01  doi:10.1186/gb-spotlight-20030102-01


The electronic version of this article is the complete one and can be found online at:


Published:2 January 2003

© 2003 BioMed Central Ltd

Research news

In an Advanced Online Publication in Nature Biotechnology, Paul Mintz and colleagues at the University of Texas M.D. Anderson Cancer Center in Texas, describe the use of phage-display technology to examine the repertoire of circulating, anti-tumour antibodies in the blood of prostate cancer patients (Nature Biotechnology, 23 December 2002, DOI:10.1038/nbt774). To characterise the 'fingerprint' of circulating antibodies they screened a phage random-peptide library with purified immunoglobulins from the serum of cancer patients and identified a number of immunoreactive peptide motifs. Reactivity correlated with disease progression and poor clinical prognosis. The anti-peptide antibodies recognise the glucose-regulated protein GRP78 which was also upregulated in metastatic prostate cancer.

References

  1. [http://www.nature.com/naturebiotechnology] webcite

    Nature Biotechnology

  2. [http://www.mdacc.tmc.edu ] webcite

    University of Texas M.D. Anderson Cancer Center

  3. The glucose-regulated proteins: stress induction and clinical applications.

    PubMed Abstract | Publisher Full Text OpenURL